

Table 1. Characteristics of 121 patients and comparison of those with wild-type versus mutant *GNAS*

	All patients (n=121)	<i>GNAS</i> wildtype (n=52)	<i>GNAS</i> mutant (n=69)	p-value
Clinical characteristics				
Age (years)	48.0 (39.0–59.5)	46.5 (40.0–60.5)	49.0 (38.5–59.5)	0.763
Sex, n (male/female)	51/70	20/32	31/38	0.577
Basal GH (ng/mL)	15.7 (7.2–34.1)	13.4 (4.6–31.3)	16.9 (8.3–48.5)	0.061
IGF-1 (ng/mL)	630.0 (473.0–817.5)	602.0 (448.0–829.3)	237.5 (505.0–817.5)	0.745
IGF-1 SDS	7.0 ± 2.4	7.2 ± 2.6	6.9 ± 2.3	0.58
PRL (ng/mL)	13.4 (8.1–29.1)	10.3 (7.4–21.0)	20.2 (9.8–37.3)	0.005
GH change by octreotide test (%)	–87.7 (–93.9 to –61.3)	–83.4 (–92.0 to –57.1)	–89.6 (–95.0 to –69.6)	0.063
GH change by bromocriptine test (%)	–65.6 (–83.8 to –23.7)	–39.3 (–68.0 to –7.3)	–79.1 (–90.2 to –55.4)	0.000
Tumor volume (mm ³)	1633.1 (651.9–4412.4)	2323.7 (1020.3–4990.0)	1135.4 (406.2–3493.1)	0.023
Knosp grade 0–2/3–4, n	93/28	33/19	60/9	0.004
Preoperative therapy				
Preoperative SSA treatment, n (%)	67 (55.4%)	33 (63.5%)	34 (49.3%)	
GH change by preoperative SSA (%)	–78.9 (–90.8 to –48.1)	–55.5 (–80.8 to –41.7)	–83.2 (–92.7 to –64.2)	0.007
Tumor volume change by preoperative SSA (%)	–23.1 ± 21.3	–19.9 ± 18.6	–26.2 ± 23.5	0.237
Postoperative profile				
Detected postoperative profile, n	80	36	44	
Postoperative treatment, n (%)	16 (20%)	8 (22.2%)	8 (18.2%)	0.78

GH, growth hormone; PRL, prolactin; SSA, somatostatin analog